David Rubin, MD, of University of Chicago Medicine, and colleagues conducted a randomized, double-blind, placebo-controlled multicenter study evaluating the drug’s safety in 510 adults. Researchers administered a once-daily 9mg oral budesonide multimatrix tablet or a placebo for eight weeks.
Here’s what you should know.
1. Approximately 13 percent of budesonide multimatrix patients achieved clinical and endoscopic remission by week eight compared to 7.5 percent of placebo patients.
2. Clinical remission was similar in both groups.
3. More budesonide multimatrix patients achieved endoscopic remission and histological healing compared to the placebo group.
4. Adverse event rates were similar.
Researchers concluded, “Budesonide multimatrix was safe and efficacious for inducing clinical and endoscopic remission for mild to moderate ulcerative colitis refractory to oral mesalamine therapy.”
More articles on gastroenterology:
Barnes-Jewish Hospital names Dr. Matthew Mutch chair of colon and rectal surgery — 4 insights
GI leader to know: Dr. Lesley Dawravoo of Digestive Health Services, SC
University Medical Center of Princeton opens Center for Digestive Health — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
